Compare CADL & FDUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CADL | FDUS |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 694.6M | 765.9M |
| IPO Year | 2021 | 2011 |
| Metric | CADL | FDUS |
|---|---|---|
| Price | $10.65 | $19.82 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 3 |
| Target Price | $19.00 | ★ $21.00 |
| AVG Volume (30 Days) | ★ 1.1M | 319.4K |
| Earning Date | 05-14-2026 | 05-07-2026 |
| Dividend Yield | N/A | ★ 11.49% |
| EPS Growth | ★ 58.62 | N/A |
| EPS | N/A | ★ 1.14 |
| Revenue | ★ $125,000.00 | N/A |
| Revenue This Year | N/A | $9.39 |
| Revenue Next Year | N/A | $8.79 |
| P/E Ratio | ★ N/A | $17.40 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.35 | $16.87 |
| 52 Week High | $11.36 | $21.67 |
| Indicator | CADL | FDUS |
|---|---|---|
| Relative Strength Index (RSI) | 60.63 | 50.00 |
| Support Level | $9.18 | $19.27 |
| Resistance Level | $11.36 | $20.25 |
| Average True Range (ATR) | 0.47 | 0.47 |
| MACD | 0.04 | -0.05 |
| Stochastic Oscillator | 87.00 | 38.00 |
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
Fidus Investment Corp is an externally managed, closed-end, non-diversified management investment company that has elected to be treated as a business development company. The company provides customized debt and equity financing solutions to lower middle-market companies. Its investment objective is to provide attractive risk-adjusted returns by generating both current income from debt investments and capital appreciation from equity related investments. The company's portfolio of investment is comprised of securities of companies from different industries such as, Information Technology Services, Business Services, Healthcare Products among others.